Claire Skentelbery’s Post

Excellent discussion about the General Pharma Legislation #GPL at Nordic Life Science Days, with SwedenBIO and European Medicines Agency. With Jessica Martinsson and Falk Ehmann, we talked about how this generational change for medicines will shape what biotechnology innovation looks like for patients and national ecosystems, sitting within changing global and financial landscape. How AI, big data and real world evidence finds its way to benefit patients, the significance of regulatory sandboxes for breakthrough medicines particularly in unmet medical needs #UMN, how to use incentives to protect Europe's previous innovation flow and the role of stakeholders (ministries, governments, MEPs...) in getting the GPL right, with a critical phase going on right now in Brussels. It is critical for biotech innovators to be part of this discussion, form starts up through to global companies as they will be the ones travelling through the pipeline to patients and hold the shape of our future healthcare in their portfolios. Thanks to the great interventions from BioArctic (Gunilla Osswald), AstraZeneca (Pernilla Isberg), Janet Hoogstraate and Malin Eklund. EuropaBio - the European Association for Bioindustries

  • No alternative text description for this image
Jessica Martinsson

Director General & CEO SwedenBio

11mo

A big thanks to you both for your contribution. Very nice summaries of both the legislative and regulatory side and a good starting point for further collaboration.

To view or add a comment, sign in

Explore topics